vs
EXPONENT INC（EXPO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是EXPONENT INC的1.4倍（$207.3M vs $147.4M），EXPONENT INC净利率更高（16.8% vs -62.0%，领先78.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -73.6%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 0.9%）
Exponent Inc.是美国知名工程与科学咨询企业，汇集科学家、医师、工程师及商业咨询专家，可在90余个技术领域开展研究与分析工作，目前在美国本土设有20个办事处，境外另有5个办事网点。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EXPO vs RARE — 直观对比
营收规模更大
RARE
是对方的1.4倍
$147.4M
营收增速更快
RARE
高出99.5%
-73.6%
净利率更高
EXPO
高出78.8%
-62.0%
两年增速更快
RARE
近两年复合增速
0.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $147.4M | $207.3M |
| 净利润 | $24.8M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 19.8% | -54.7% |
| 净利率 | 16.8% | -62.0% |
| 营收同比 | -73.6% | 25.9% |
| 净利润同比 | -77.3% | 3.5% |
| 每股收益（稀释后） | $0.49 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXPORARE
| Q4 25 | $147.1M | $207.3M | ||
| Q3 25 | $142.0M | $159.9M | ||
| Q2 25 | $145.5M | $166.5M | ||
| Q1 25 | $136.8M | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | $136.3M | $139.5M | ||
| Q2 24 | $140.5M | $147.0M | ||
| Q1 24 | $144.9M | $108.8M |
净利润EXPORARE
| Q4 25 | $28.0M | $-128.6M | ||
| Q3 25 | $26.6M | $-180.4M | ||
| Q2 25 | $26.6M | $-115.0M | ||
| Q1 25 | $23.6M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $26.0M | $-133.5M | ||
| Q2 24 | $29.2M | $-131.6M | ||
| Q1 24 | $30.1M | $-170.7M |
营业利润率EXPORARE
| Q4 25 | 19.7% | -54.7% | ||
| Q3 25 | 12.1% | -106.9% | ||
| Q2 25 | 30.5% | -64.8% | ||
| Q1 25 | 19.9% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 19.0% | -94.6% | ||
| Q2 24 | 25.4% | -79.1% | ||
| Q1 24 | 21.2% | -151.9% |
净利率EXPORARE
| Q4 25 | 19.1% | -62.0% | ||
| Q3 25 | 18.7% | -112.8% | ||
| Q2 25 | 18.3% | -69.0% | ||
| Q1 25 | 17.2% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 19.1% | -95.7% | ||
| Q2 24 | 20.8% | -89.5% | ||
| Q1 24 | 20.8% | -156.8% |
每股收益（稀释后）EXPORARE
| Q4 25 | $0.55 | $-1.28 | ||
| Q3 25 | $0.52 | $-1.81 | ||
| Q2 25 | $0.52 | $-1.17 | ||
| Q1 25 | $0.45 | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | $0.50 | $-1.40 | ||
| Q2 24 | $0.57 | $-1.52 | ||
| Q1 24 | $0.59 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $221.9M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $390.3M | $-80.0M |
| 总资产 | $777.5M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXPORARE
| Q4 25 | $207.4M | $421.0M | ||
| Q3 25 | $231.8M | $202.5M | ||
| Q2 25 | $245.1M | $176.3M | ||
| Q1 25 | $258.9M | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | $219.7M | $150.6M | ||
| Q2 24 | $203.3M | $480.7M | ||
| Q1 24 | $168.7M | $112.3M |
股东权益EXPORARE
| Q4 25 | $402.9M | $-80.0M | ||
| Q3 25 | $427.8M | $9.2M | ||
| Q2 25 | $441.4M | $151.3M | ||
| Q1 25 | $421.1M | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | $410.3M | $346.8M | ||
| Q2 24 | $393.2M | $432.4M | ||
| Q1 24 | $374.3M | $140.3M |
总资产EXPORARE
| Q4 25 | $761.4M | $1.5B | ||
| Q3 25 | $759.4M | $1.2B | ||
| Q2 25 | $763.2M | $1.3B | ||
| Q1 25 | $777.3M | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $744.1M | $1.5B | ||
| Q2 24 | $709.2M | $1.6B | ||
| Q1 24 | $629.4M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流EXPORARE
| Q4 25 | $32.7M | $-99.8M | ||
| Q3 25 | $36.2M | $-91.4M | ||
| Q2 25 | $7.3M | $-108.3M | ||
| Q1 25 | $56.1M | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | $29.7M | $-67.0M | ||
| Q2 24 | $48.3M | $-77.0M | ||
| Q1 24 | $10.4M | $-190.7M |
自由现金流EXPORARE
| Q4 25 | $30.0M | $-100.8M | ||
| Q3 25 | $33.9M | $-92.7M | ||
| Q2 25 | $5.5M | $-110.7M | ||
| Q1 25 | $53.5M | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | $28.0M | $-68.6M | ||
| Q2 24 | $47.2M | $-79.0M | ||
| Q1 24 | $8.9M | $-193.9M |
自由现金流率EXPORARE
| Q4 25 | 20.4% | -48.6% | ||
| Q3 25 | 23.9% | -58.0% | ||
| Q2 25 | 3.8% | -66.5% | ||
| Q1 25 | 39.1% | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | 20.5% | -49.2% | ||
| Q2 24 | 33.6% | -53.7% | ||
| Q1 24 | 6.2% | -178.2% |
资本支出强度EXPORARE
| Q4 25 | 1.8% | 0.5% | ||
| Q3 25 | 1.6% | 0.8% | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 1.9% | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 1.3% | 1.2% | ||
| Q2 24 | 0.8% | 1.4% | ||
| Q1 24 | 1.0% | 3.0% |
现金转化率EXPORARE
| Q4 25 | 1.16× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 2.38× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.65× | — | ||
| Q1 24 | 0.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXPO
| Revenues before reimbursements | $123.8M | 84% |
| Reimbursements | $18.0M | 12% |
| Other | $5.6M | 4% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
